This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Merck (MRK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $82.95, marking a +1.28% move from the previous day.
Celyad-Merck Team Up to Evaluate CYAD-101 in Colorectal Cancer
by Zacks Equity Research
Celyad Oncology (CYAD) collaborates with Merck to evaluate its CAR-T candidate, CYAD-101,combined with the latter's Keytruda in microsatellite stable refractory metastatic colorectal cancer.
Eiger Down on Disappointing Results From Coronavirus Study
by Zacks Equity Research
Eiger (EIGR) declines on disappointing study results on candidate, peginterferon lambda-1a (lambda), in outpatients with mild and uncomplicated COVID-19.
Why Merck (MRK) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Bristol-Myers' Opdivo Meets Goals in Bladder Cancer Study
by Zacks Equity Research
Bristol-Myers' (BMY) Opdivo meets primary endpoint in a phase III study in patients with urothelial carcinoma.
Pharma Stock Roundup: J&J's Coronavirus Vaccine in Phase III, Other Updates
by Kinjel Shah
J&J (JNJ) becomes the fourth company to start a phase III study on its coronavirus vaccine candidate. CHMP recommends approval of several drugs.
Merck (MRK) Stock Moves -0.37%: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $82.63, marking a -0.37% move from the previous day.
Glaxo's Zejula Gets Positive CHMP View for First-Line Setting
by Zacks Equity Research
The CHMP's favorable response recommends the regulatory nod for GlaxoSmithKline's (GSK) Zejula as the first-line maintenance treatment of ovarian cancer patients regardless of the biomarker status.
Seattle Genetics' Padcev Study Aids Urothelial Cancer Survival
by Zacks Equity Research
Seattle Genetics' (SGEN) phase III EV-301 study on Padcev meets the main goal of overall survival compared to chemotherapy in patients previously treated for locally advanced/metastatic urothelial cancer.
Pharma Stock Roundup: AZN, LLY & PFE's Coronavirus Updates, MRK's New Cancer Deals
by Kinjel Shah
AstraZeneca (AZN) resumes its coronavirus vaccine study in the United Kingdom. Merck (MRK) inks two oncology deals with Seattle Genetics.
Corcept's Lead Drug Korlym Aids Growth, Heavy Reliance a Woe
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym shows a steady progress. Other pipeline candidates are advancing as well. However, heavy dependence on Korlym for growth remains an overhang.
Bristol-Myers' Opdivo+Yevroy Application Gets EMA Validation
by Zacks Equity Research
Bristol Myers Squibb (BMY) gets EMA validation for a type II variation application for its Opdivo+Yervoy combination to treat previously untreated, unresectable malignant pleural mesothelioma.
Lilly Drug Gets Fast Track to Improve Heart Attack Outcome
by Zacks Equity Research
Lilly's (LLY) EMPACT-MI study is part of Jardiance's ENPOWER clinical program, which is studying the impact of Jardiance on major clinical cardiovascular and renal outcomes in a spectrum of cardio-renal-metabolic conditions.
Merck (MRK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $84.21, moving +0.06% from the previous trading session.
Seattle Genetics Up on Two New Oncology Deals With Merck
by Zacks Equity Research
Seattle Genetics (SGEN) strikes a couple of deals with Merck to co-develop ladiratuzumab vedotin for breast cancer and other solid tumors. Also, Merck will market the company's Tukysa in some places.
Merck Buys Rights to Co-Develop Seattle Genetics ADC Drug
by Zacks Equity Research
Merck (MRK) buys rights to co-develop/co-commercialize Seattle Genetics' ladiratuzumab vedotin. It acquires exclusive license to commercialize Tukysa for HER2-positive cancers in Asia, the Middle East and Latin America
Stock Market News for Sep 15, 2020
by Zacks Equity Research
U.S. stock markets closed higher on Monday reversing some of the losses of the last week.
M&A Activities Intensify in Pharma Industry
by Zacks Equity Research
M&A Activities Intensify in Pharma Industry.
No Econ Data, but Big Biopharma News
by Mark Vickery
Merck, Gilead and Lilly make progress on an otherwise slow news day.
Pharma Stock Roundup: AZN & PFE's Coronavirus Vaccine Updates & FDA Approvals
by Kinjel Shah
AstraZeneca (AZN) halts coronavirus vaccine study. FDA approves Roche (RHHBY) and Glaxo's (GSK) medicines.
Zacks Market Edge Highlights: MRK, ABBV, PXD, VBR and VIOO
by Zacks Equity Research
Zacks Market Edge Highlights: MRK, ABBV, PXD, VBR and VIOO
Merck's Pneumococcal Vaccine Meets Goals in Late-Stage Studies
by Zacks Equity Research
Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.
Merck (MRK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $84.88 in the latest trading session, marking a +1.86% move from the prior day.
Generation X Investors: Deja Vu?
by Tracey Ryniec
Generation X investors came of age in the dot-com boom when Microsoft and other tech titans hit new highs. Now, in 2020, it's happening again.
Merck Announces Detailed Data on Late-Stage Cough Candidate
by Zacks Equity Research
Merck (MRK) announced detailed data from two pivotal studies evaluating gefapixant in patients with refractory or unexplained chronic cough.